Therapeutic depth, not shelf space
We deliberately specialize in high-complexity therapy areas — oncology, immunology, and rare diseases — where commercial success depends on scientific depth, not shelf space.
Your integrated commercial partner for innovative specialty therapies in Croatia and Slovenia — from EU marketing authorization to the first prescription and beyond.
A licensed pharmaceutical wholesaler and commercialization platform focused on oncology, immunology, and rare diseases across two EU Member States with harmonized regulatory pathways.
Supreme Pharma is a licensed pharmaceutical wholesale and commercialization company dedicated to bringing innovative specialty therapies to patients across the Croatian and Slovenian healthcare markets.
We are not a logistics-only distributor. Together with our sister company Dedal komunikacije — a specialized pharmaceutical marketing and medical affairs agency — we operate as a single, accountable commercial platform.
This lets manufacturers outsource their full go-to-market — regulatory liaison, market access, KOL engagement, medical promotion, hospital tendering, and last-mile distribution — to one partner across both markets, with combined GDP of EUR 130+ billion and harmonized EU regulatory pathways.
We combine a specialist therapeutic focus with an integrated commercial and medical platform — built for innovators who need scientific depth rather than volume distribution.
We deliberately specialize in high-complexity therapy areas — oncology, immunology, and rare diseases — where commercial success depends on scientific depth, not shelf space.
Distribution, medical marketing, KOL relationships, and market access live under one roof. One contract, one team, full accountability from EU approval through reimbursement to in-market performance.
Croatia and Slovenia as EU Member States enable streamlined regulatory pathways (CP / MRP / DCP) and serve as a natural launchpad into the wider Adriatic region.
The combination of Supreme Pharma and Dedal komunikacije is what most manufacturers cannot build locally without significant time and capital — and what most local distributors cannot offer.
A full-service commercial partner — from regulatory and access to promotion and distribution.
We prioritize categories where scientific complexity, prescriber education, and access expertise create real differentiation — and where an integrated platform outperforms generalist distributors.
For specialty therapies, the difference between a successful launch and a stalled one is rarely the molecule — it is the depth of the local commercial partnership. We are built to be that depth. — Supreme Pharma
We adapt the commercial structure to your product, lifecycle stage, and existing EU footprint. Below are the most common configurations — and we welcome bespoke arrangements.
You retain EU Marketing Authorization (CP / MRP / DCP). We act as your local commercial partner: importation, distribution, hospital tendering, medical promotion via Dedal, KOL engagement, market access submissions to HZZO/ZZZS, and pharmacovigilance liaison.
For manufacturers with a partial EU footprint who need a dedicated local team. We deploy medical representatives, run scientific programs, manage KOL relationships, and handle local distribution under your strategic direction.
For products without existing EU registration, we can act as Marketing Authorization Holder or named local representative through HALMED and JAZMP, reducing your regulatory burden while you retain full commercial governance.
For mature products or lifecycle extensions, we explore co-promotion structures and in-licensing arrangements that align with our therapeutic focus and ecosystem.
Smaller markets are often viewed as commercial afterthoughts. We see them as strategic anchors: high-quality EU regulatory standing, sophisticated specialist communities, and predictable reimbursement — at a fraction of the operational cost of larger EU markets.
If your portfolio includes an innovative specialty therapy considering or already pursuing entry into Croatia and Slovenia, we would welcome an exploratory conversation under mutual confidentiality.